ABSTRACT
INTRODUCTION
Although preeclampsia is associated with increased maternal and perinatal morbidity and mortality worldwide, our understanding of its pathophysiology and etiology is still incomplete. But it is beyond doubt that the placenta contributes to the pathogenesis of preeclampsia because its development requires the presence of the placenta and delivery of the placenta is the most effective way to treat preeclampsia.
Last 6 years some research findings support the hypothesis that the symptoms are related to a decrease in free vascular endothelial growth factor (VEGF) in the maternal blood, as a result of capture by sFlt1, the soluble form of VEGF-receptor1 [1] . However, not all women with preeclampsia have increased sFlt1 and endoglin concentrations. And further upstream, the mechanisms at work in the primary placental defect are unknown. Recently, an ex vivo study using genetic COMT knockout mice suggested that placental COMT deficiency induced preeclampsia due to an absence of 2-methoxyestradiol (2-ME), a product of COMT. Administration of 2-ME to COMT-deficient mice reverts the PE-like phenotype without toxicity [2] . Moreover, 2-ME has been shown to facilitate the development of the placenta and embryo by promoting the establishment of the uteroplacental circulation under hypotic conditions [3] . Together, these results suggest that COMT and 2-ME deficiency might play a significant role in the development of preeclampsia. Although these studies provide an attractive hypothesis implicating reduced COMT expression in the pathogenesis of preeclampsia, clinical evidence confirming that reduced COMT expression occurs in preeclampsia has been limited. Furthermore, placentas obtained from pregnancies complicated by term preeclampsia have not been investigated. The early-onset preeclampsia may be responsible for the largest burden of perinatal and maternal morbidity and mortality. But in some cases, late-onset preeclampsia is also lifethrea-tening to the mother and fetus [4] . Therefore, we decided to conduct a case-control study to investigate placental COMT expression in patients with term preeclampsia in a Chinese cohort.
cruited from the department of obstetrics at Shenzhen Maternity and Child Healthcare Hospital between April 2012 and August 2012. The local ethical committee approved this study and written informed consent was obtained from all the patients. Placental tissue was obtained during the deliveries by cesarean section from normal term pregnancies (n = 15) and term pregnancies complicated by preeclampsia (n = 15). Preeclampsia was defined as a pregnancy-specific syndrome that occurred after 20 weeks of gestation and was characterized by systolic pressure of 140 mmHg or higher or diastolic pressure of 90 mmHg or higher on two occasions longer than 6 hours apart, occurring with proteinuria (>300 mg/ day).
Placental tissue was collected immediately after delivery by caesarean section. Tissue was obtained from the maternal site of the placenta, about 3 cm from the area of the cord insertion. Specimens were cut into small pieces and washed with ice-cold PBS. Samples for collected for RNA extraction were immersed in RNAlater (Ambion) overnight at 4˚C and transferred to −20˚C for long-term storage. Samples for immunohistochemistry were fixed in 4% formalin.
Real-Time PCR
Total RNA from placental samples (50 mg) was obtained using 1 ml of Trizol (Invitrogen) according to the manufacturer's instructions. At the end of the procedure, RNA pellets were briefly air-dried for 10 min, dissolved in DEPC water. RNA purity and concentration were verified using a Nanodrop spectrophotomer (Thermo Scientific); all RNA samples had an A 260 /A 280 ratio of 1.80 -2.0. Total RNA was reverse-transcribed to cDNA in a 20 μl reaction using oligo-dT primers according to manufacturer's protocol (MBI). cDNA was diluted with nuclease-free water (Thermo Scientific). Real-time PCR analysis was then performed in a fluorescent temperature cycler (SYBR Green dye (TaKaRa)) to examine the mRNA level of COMT in placental tissue with LightCycler 480 (Roche) according to the manufacturer's instructions. The PCR cycling conditions included an initial denaturation at 95˚C for 10 seconds, followed by 50 cycles at 95˚C for 5 seconds, 55˚C for 8 seconds, and 72˚C for 12 seconds. The sequences of the PCR primer pairs for COMT (84 bp) and GAPDH (110 bp) were fellows. For COMT, forward primer was 5'-TCCTTCTCAACTGCCATTCC-3', reverse primer was 5'-CCTTAGCGTTAGCGTCCG TC-3'. For GAPDH, forward primer was 5'-CAAGAAGGTGGTGAAGCAGG-3', reverse primer was 5'-AGGTGGAGGAGTGGGTGTCG-3' (Invitrogen). The cycle threshold values and COMT relative values were obtained using the software provided by the manufacturer.
Immunohistochemistry
The placentas were fixed in 4% formalin for 12 to 24 hours, embedded in paraffin and cut into 4-μm sections. The sections were first deparaffinised by immersion in xylene followed by rehydration by passing through descending concentrations of alcohol (100% -70%) and finally immersion in running tap water. Antigen retrieval was performed by microwave heating these sections for 10 min in trisodium citrate buffer (10 mM) sodium citrate, PH 6.0). Sections were then washed with PBS. Slides were then incubated for 2 h at room temperature with Rabbit anti human COMT polyclonal antibody (1:40, Abcam). After three times washing sections were incubated with MaxVision solution (Maixin Bio, China) for 30 min. The staining was detected with DAB chromogen after 5 min. The nuclei were counterstained by incubation with hematoxylin for 2 min. The sections were mounted, examined and photographed. Specificity of staining was confirmed using positive control tissue. Negative controls were also performed in each staining run using no primary antibody.
Immunohistochemical Semiquantification
15 images from each group were taken with the microscope settings unaltered. Semiquantitative analysis of COMT expression based on the combination of staining intensity of immuno-histochemical images with the percentage of positive cells was performed by a published method [5] . Briefly, no staining is scored as 0, 1% -10% of positive cells stained scored as 1, 11% -50% as 2, 51% -80% as 3, and 81% -100% as 4. Staining intensity is rated on a scale of 0 -3, with 0 = negative; 1 = weak; 2 = moderate, and 3 = strong. The raw data were converted by multiplying the quantity and staining intensity scores. Negative controls were stained without primary antibody.
Statistical Analysis
Statistical analyses were performed with SPSS software version 13.0. Clinical characteristics and placental COMT mRNA data were presented as mean ± standard deviation (SD). The statistical significance of the results was assessed by t test. The associations between COMT mRNA and clinical parameters were analyzed by partial correlation. The data from the semiquantification of immunoThe characteristics of patients are summarised in Table 1 . The MAP, BMI and serum uric acid level were significantly higher in pregnant women with preeclampsia (P < 0.05). There were no significant difference in maternal age, gestational age and birth weight of infants between normal pregnancies and pregnancies with preeclampsia (P > 0.05).
OPEN ACCESS

Placental COMT-mRNA Level and Its Correlation with Clinical Parameters
COMT-mRNA of all placentas was detected. The mRNA level of COMT in preeclamptic placentas was significantly decreased compared to that in gestation-matched normal placentas (P < 0.001, Figure 1) . When control the BMI, the level of COMT-mRNA in preeclamptic group was negatively correlated with MAP, serum uric acid and 24-hour urine protein (all P < 0.001, Table 2 ).
Expression and Immunolocalization of COMT in Placentas
The cells that produce COMT in the placenta were identified with immunohistochemistry. COMT was primarily detected in the syncytiotrophoblasts of the placentas from preeclamptic women. A similar but more intense staining pattern was observed in the same cell types of the placentas from the normal pregnant women (Figure 2) . Semiquantitative analysis indicated this reduced expression of COMT in preeclamptic placentas was significant (P < 0.05) (Figure 3) . 
DISCUSSION
In this study we confirmed that reduced placental expression of COMT in preeclampsia compared with control term pregnancy at both the mRNA and protein levels. It was also demonstrated COMT-mRNA expression was negatively correlated with MAP, serum uric acid and 24-hour urine protein.
COMT is a key enzyme involved in catecholamine and estrogen degradation [6] . It is active in both placenta and deciduas [7, 8] . Decreased placental COMT activity was first reported to be associated with hypertension in pregnancy [7] . More recently, Kanasaki et al. demonstrated that pregnant mice deficient in COMT develop multiple functional and structural features of preeclampsia-like phenotype due to absence of 2-ME which is a metabolite of 17β-esteradiol generated by COMT [2] . Administration of 2-ME rescued the COMT-deficient mice from the preeclampsia-like syndrome without toxicity. The authors demonstrated that reduced placental COMT expression in the pathophysiology characteristics of preeclampsia. And this was confirmed by the pharmacologic study, in which the inhibition of COMT induced manifestations of preeclampsia in normal pregnant mice. And normal pregnant mice developed preeclampsia when given an inhibitor of a precursor of the 2-ME protein. But the clinical evidence about relationship between COMT and preeclampsia has been limited and inconsistent. Kanasaki examined placental COMT protein expression in only 6 preeclampsia women in the third trimester and Lee just 3 severe preeclampsia placentas [2, 3] . Consistent with the results of Lee and Kanasaki, our study using placentas from term pregnancy at both the mRNA and protein levels confirmed an association between reduced COMT expression and preeclampsia. However, in the early onset severe preeclampsia group, Palmer reported that placental COMT expression was not different from that of term or preterm normotensive pregnant women at both the mRNA and protein levels [9] . Very recently, Seol also reported that placental COMT expression was not different between women with late onset severe preeclampsia and term normal pregnant women at protein level [10] . These discrepancies can be partially explained by the use of different study populations and detection methods. Furthermore, the studies had some limitations. The control group in Palmer's research included 14 normal-term pregnancies and 8 preterm pregnancies complicated by some diseases but not preeclampsia. The research compared the placental COMT mRNA level between the term pregnancies and the early-onset preeclampsia, and the gestational age was significantly different between the two groups (38.5 vs 31, P < 0.001). The same limitation existed in Seol's study (gestational age: 38.1 vs 36.0, P = 0.015). There were no significant differences between the two groups with respect to gestational age in our study (38.45 vs 38.86, P > 0.05).
MAP, serum uric acid and urine protein were important indexes reflecting the severity of preeclampsia. This research firstly investigated the association between placental COMT expression and them in preeclampsia. We found placental COMT expression was significantly negatively correlated with serum uric acid, urine protein and MAP respectively.
CONCLUSION
In conclusion, this study shows that the COMT mRNA and protein are reduced in placentas from term preeclampsia patients, and this is negatively correlated with MAP, uric acid and urine protein suggesting a role in the pathophysiological changes that occur in this disorder. Further longitudinal investigations regarding placental COMT polymorphism and 2-ME level are needed to explore the role of COMT in the pathophysiology of preeclampsia.
